New pill combo aims to control rare blood cancer
NCT ID NCT06547866
Summary
This study is testing whether a combination of two oral drugs, zanubrutinib and BGB-11417, can effectively control a rare blood cancer called Waldenström's macroglobulinemia in patients whose disease has returned after prior treatment. The goal is to see if this limited-duration treatment (about 18 months) can achieve deep responses. The trial will enroll 102 adults in France to evaluate the treatment's effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AMIENS - CH Amiens Picardie Site Sud
Amiens, 80054, France
-
ANNECY - CH Annecy Genevois
Annecy, 74374, France
-
APHP - Hôpital Pitié Salpêtrière - Hématologie
Paris, 75651, France
-
ARGENTEUIL - Centre hospitalier Victor Dupouy
Argenteuil, France
-
Angers Chu
Angers, 49933, France
-
BAYONNE - CH de la Côte Basque - Hématologie
Bayonne, 64109, France
-
BESANCON - Hôpital Jean Minjoz
Besançon, 25000, France
-
Bordeaux Pessac
Pessac, 33604, France
-
Bordeaux-Institut Bergonié
Bordeaux, 33076, France
-
CAEN - CHU Caen - IHBN
Caen, 14033, France
-
CRETEIL - CHU Henri Mondor
Créteil, 94000, France
-
Clermont-Ferrand - Chu Estaing
Clermont-Ferrand, 63000, France
-
DIJON - Hôpital François Mitterrand
Dijon, 21000, France
-
Grenoble - CHUGA - Hématologie Clinique
Grenoble, 38043, France
-
LILLE CHU - Hôpital Claude Huriez
Lille, 59037, France
-
LILLE GHICL - Hôpital Saint Vincent de Paul
Lille, 59000, France
-
LYON HCL - CH Lyon Sud
Pierre-Bénite, 69036, France
-
LYON-Centre Léon Bérard
Lyon, 69008, France
-
La Roche Sur Yon - Chd Vendee
La Roche-sur-Yon, 85925, France
-
Le Mans CH
Le Mans, France
-
MARSEILLE - Institut Paoli-Calmettes
Marseille, 13000, France
-
MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique
Montpellier, 34295, France
-
Mulhouse - Ghrmsa
Mulhouse, 68100, France
-
NANCY - CHU Brabois
Vandœuvre-lès-Nancy, 54500, France
-
NANTES - Hôpital Hôtel Dieu - Hématologie Clinique
Nantes, 44093, France
-
ORLEANS - CHR - Hématologie
Orléans, 44100, France
-
PERPIGNAN - CH St Jean - Hématologie Clinique
Perpignan, 66000, France
-
POITIERS - Hématologie et Thérapie Cellulaire
Poitiers, 86021, France
-
RENNES - CHU Pontchaillou - Hématologie Clinique
Rennes, 35033, France
-
ROUEN - Centre Henri Becquerel - Service Hématologie Clinique
Rouen, 76038, France
-
Reims Chu
Reims, 51092, France
-
Strasbourg - Icans
Strasbourg, 67033, France
-
TOURS - Hôpital Bretonneau
Tours, 37000, France
-
Toulouse - IUCT Oncopole - Service d'Hématologie
Toulouse, 31059, France
-
VERSAILLES - Hôpital André Mignot
Versailles, France
-
Vannes - Chba
Vannes, France
-
Villejuif Igr
Villejuif, France
Conditions
Explore the condition pages connected to this study.